TY - STD TI - Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, et al. Phase III trial of adjuvant capecitabine after standard neo−/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020;38(3):203–13. https://doi.org/10.1200/JCO.19.00904. ID - ref1 ER - TY - JOUR AU - Barton, M. K. PY - 2015 DA - 2015// TI - Patients of all ages with advanced non-small cell lung cancer are not receiving chemotherapy JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21290 DO - 10.3322/caac.21290 ID - Barton2015 ER - TY - STD TI - Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18(20):3558–85. https://doi.org/10.1200/JCO.2000.18.20.3558. ID - ref3 ER - TY - STD TI - Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A(3):319–24. ID - ref4 ER - TY - STD TI - Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164–70. https://doi.org/10.1056/NEJM199107183250305. ID - ref5 ER - TY - STD TI - Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178–84. https://doi.org/10.1200/JCO.2005.09.102. ID - ref6 ER - TY - STD TI - Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727–31. https://doi.org/10.1200/JCO.2002.20.3.727. ID - ref7 ER - TY - STD TI - Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35. https://doi.org/10.1093/annonc/mdg019. ID - ref8 ER - TY - STD TI - Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–205. https://doi.org/10.1200/JCO.2006.06.4451. ID - ref9 ER - TY - JOUR AU - Welte, K. AU - Gabrilove, J. AU - Bronchud, M. H. AU - Platzer, E. AU - Morstyn, G. PY - 1996 DA - 1996// TI - Filgrastim (r-metHuG-CSF): the first 10 years JO - Blood VL - 88 UR - https://doi.org/10.1182/blood.V88.6.1907.bloodjournal8861907 DO - 10.1182/blood.V88.6.1907.bloodjournal8861907 ID - Welte1996 ER - TY - JOUR AU - Demetri, G. D. AU - Griffin, J. D. PY - 1991 DA - 1991// TI - Granulocyte colony-stimulating factor and its receptor JO - Blood VL - 78 UR - https://doi.org/10.1182/blood.V78.11.2791.bloodjournal78112791 DO - 10.1182/blood.V78.11.2791.bloodjournal78112791 ID - Demetri1991 ER - TY - JOUR AU - Ozer, H. PY - 1996 DA - 1996// TI - American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors JO - Curr Opin Hematol VL - 3 UR - https://doi.org/10.1097/00062752-199603010-00002 DO - 10.1097/00062752-199603010-00002 ID - Ozer1996 ER - TY - STD TI - Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15):2433–53. https://doi.org/10.1016/j.ejca.2006.05.002. ID - ref13 ER - TY - JOUR AU - Layton, J. E. AU - Hockman, H. AU - Sheridan, W. P. AU - Morstyn, G. PY - 1989 DA - 1989// TI - Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor JO - Blood VL - 74 UR - https://doi.org/10.1182/blood.V74.4.1303.1303 DO - 10.1182/blood.V74.4.1303.1303 ID - Layton1989 ER - TY - JOUR AU - Kuwabara, T. AU - Kato, Y. AU - Kobayashi, S. AU - Suzuki, H. AU - Sugiyama, Y. PY - 1994 DA - 1994// TI - Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans JO - J Pharmacol Exp Ther VL - 271 ID - Kuwabara1994 ER - TY - JOUR AU - Pelegri-O'Day, E. M. AU - Lin, E. W. AU - Maynard, H. D. PY - 2014 DA - 2014// TI - Therapeutic protein-polymer conjugates: advancing beyond PEGylation JO - J Am Chem Soc VL - 136 UR - https://doi.org/10.1021/ja504390x DO - 10.1021/ja504390x ID - Pelegri-O'Day2014 ER - TY - JOUR AU - Harris, J. M. AU - Martin, N. E. AU - Modi, M. PY - 2001 DA - 2001// TI - Pegylation: a novel process for modifying pharmacokinetics JO - Clin Pharmacokinet VL - 40 UR - https://doi.org/10.2165/00003088-200140070-00005 DO - 10.2165/00003088-200140070-00005 ID - Harris2001 ER - TY - STD TI - van Der Auwera P, Platzer E, Xu ZX, Schulz R, Feugeas O, Capdeville R, et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol. 2001;66(4):245–51. https://doi.org/10.1002/ajh.1052. ID - ref18 ER - TY - JOUR AU - Knop, K. AU - Hoogenboom, R. AU - Fischer, D. AU - Schubert, U. S. PY - 2010 DA - 2010// TI - Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives JO - Angew Chem Int Ed Engl VL - 49 UR - https://doi.org/10.1002/anie.200902672 DO - 10.1002/anie.200902672 ID - Knop2010 ER - TY - JOUR AU - Elsadek, B. AU - Kratz, F. PY - 2012 DA - 2012// TI - Impact of albumin on drug delivery--new applications on the horizon JO - J Control Release VL - 157 UR - https://doi.org/10.1016/j.jconrel.2011.09.069 DO - 10.1016/j.jconrel.2011.09.069 ID - Elsadek2012 ER - TY - STD TI - Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem. 2003;49(4):581–5. https://doi.org/10.1373/49.4.581. ID - ref21 ER - TY - STD TI - Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197(3):315–22. https://doi.org/10.1084/jem.20021829. ID - ref22 ER - TY - JOUR AU - Brønden, A. AU - Naver, S. V. AU - Knop, F. K. AU - Christensen, M. PY - 2015 DA - 2015// TI - Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy JO - Expert Opin Drug Metab Toxicol VL - 11 UR - https://doi.org/10.1517/17425255.2015.1068288 DO - 10.1517/17425255.2015.1068288 ID - Brønden2015 ER - TY - STD TI - Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, et al. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemother Pharmacol. 2015;76(4):699–712. https://doi.org/10.1007/s00280-015-2833-5. ID - ref24 ER - TY - STD TI - Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–803. https://doi.org/10.1200/JCO.2005.04.937. ID - ref25 ER - TY - JOUR AU - McHugh, J. PY - 2018 DA - 2018// TI - A cellular cascade of GM-CSF production JO - Nat Rev Rheumatol VL - 14 UR - https://doi.org/10.1038/s41584-018-0038-0 DO - 10.1038/s41584-018-0038-0 ID - McHugh2018 ER - TY - STD TI - Volovat C, Gladkov OA, Bondarenko IM, Barash S, Buchner A, Bias P, et al. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy. Clin Breast Cancer. 2014;14(2):101–8. https://doi.org/10.1016/j.clbc.2013.10.001. ID - ref27 ER - TY - STD TI - Zhang X, Zhang Z, Cao M, Liu B, Mori M, Luoh SW, et al. A randomized parallel controlled phase II Trial of recombinant human endostatin added to neoadjuvant chemotherapy for stage III breast cancer. Clin Breast Cancer. 2020;20(4):291–299.e293. ID - ref28 ER - TY - JOUR AU - Liu, Y. AU - Xu, Z. AU - Zhang, Z. AU - Wen, G. AU - Sun, J. AU - Han, F. PY - 2019 DA - 2019// TI - Efficacy and safety of TE/TEC/intensive paclitaxel neoadjuvant chemotherapy for the treatment of breast cancer JO - Oncol Lett VL - 17 UR - https://doi.org/10.3892/ol.2018.9658 DO - 10.3892/ol.2018.9658 ID - Liu2019 ER - TY - STD TI - Xu B, Shao Z, Wang S, Jiang Z, Hu X, Zhang X, et al. Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies. Chin J Cancer Res = Chung-kuo yen cheng yen chiu. 2018;30(3):327–39. ID - ref30 ER - TY - JOUR AU - Gu, X. AU - Zhang, Y. AU - Chen, L. AU - Guo, J. AU - Zhang, W. H. PY - 2015 DA - 2015// TI - Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer JO - Cancer Chemother Pharmacol VL - 75 UR - https://doi.org/10.1007/s00280-014-2646-y DO - 10.1007/s00280-014-2646-y ID - Gu2015 ER - TY - STD TI - Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica. 2008;93(3):405–12. https://doi.org/10.3324/haematol.11287. ID - ref32 ER - TY - STD TI - Gladkov O, Moiseyenko V, Bondarenko IN, Shparyk Y, Barash S, Adar L, et al. Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Med Oncol (Northwood, London, England). 2015;32(6):623. https://doi.org/10.1007/s12032-015-0623-x. ID - ref33 ER - TY - JOUR AU - Dale, D. C. AU - Rosenberg, P. S. AU - Alter, B. P. PY - 2006 DA - 2006// TI - Lineage-specific hematopoietic growth factors JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMc061587 DO - 10.1056/NEJMc061587 ID - Dale2006 ER - TY - STD TI - Gladkov O, Moiseyenko V, Bondarenko IN, Shparyk Y, Barash S, Adar L, et al. A phase III study of balugrastim versus pegfilgrastim in breast cancer patients receiving chemotherapy with doxorubicin and docetaxel. Oncologist. 2016;21(1):7–15. https://doi.org/10.1634/theoncologist.2015-0152. ID - ref35 ER -